Full Text:  <614>

CLC number: R593.2

On-line Access: 2010-10-05

Received: 2010-03-11

Revision Accepted: 2010-07-05

Crosschecked: 2010-09-13

Cited: 0

Clicked: 1212

Citations:  Bibtex RefMan EndNOte GB/T7714

Similar articles

1. Methotrexate ameliorates....

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2010 Vol.11 No.10 P.779-782

doi: 10.1631/jzus.B1000087


Infliximab treatment in two Chinese patients with psoriatic arthritis


Author(s):  Xi Xie, Jin-wei Chen, Fen Li, Jing Tian, Jie-sheng Gao, David Zhang

Affiliation(s):  1.Department of Rheumatology, the Second Xiangya Hospital, Central South University, Changsha 410011, China; Department of Bioengineering, University of Washington, Seattle, Washington 98195, USA

Corresponding email(s):  jinwei73104@yahoo.com.cn

Key Words:  Refractory psoriatic arthritis, Skin lesions, Infliximab, Anti-tumor necrosis factor alpha (TNF-α) treatment


Share this article to? More

Xi Xie, Jin-wei Chen, Fen Li, Jing Tian, Jie-sheng Gao, David Zhang. Infliximab treatment in two Chinese patients with psoriatic arthritis[J]. Journal of Zhejiang University Science B, 2010, 6(11): 779-782.

@article{0
title="Infliximab treatment in two Chinese patients with psoriatic arthritis",
author="Xi Xie, Jin-wei Chen, Fen Li, Jing Tian, Jie-sheng Gao, David Zhang",
journal="Journal of Zhejiang University Science B",
volume="11",
number="6",
pages="779-782",
year="2010",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1000087"
}

%0 Journal Article
%T Infliximab treatment in two Chinese patients with psoriatic arthritis
%A Xi Xie
%A Jin-wei Chen
%A Fen Li
%A Jing Tian
%A Jie-sheng Gao
%A David Zhang
%J Journal of Zhejiang University SCIENCE B
%V 11
%N 6
%P 779-782
%@ 1673-565X
%D 2010
%I Zhejiang University Press & Springer

TY - JOUR
T1 - Infliximab treatment in two Chinese patients with psoriatic arthritis
A1 - Xi Xie
A1 - Jin-wei Chen
A1 - Fen Li
A1 - Jing Tian
A1 - Jie-sheng Gao
A1 - David Zhang
J0 - Journal of Zhejiang University Science B
VL - 11
IS - 6
SP - 0
EP - 0
SN - 1673-565X
Y1 - 2010
PB - Zhejiang University Press & Springer
ER -


Abstract: 
Psoriatic arthritis (PsA) is a rheumatoid factor (RF)-seronegative systemic inflammatory disorder associated with psoriasis. Current treatment for PsA in China is still focused on disease modifying anti-rheumatic drugs (DMARDs). In this paper, we report two Chinese patients with active longstanding PsA treated with infliximab, a human-mouse chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α). The results show that infliximab acted quickly and effectively in relieving peripheral and axial symptoms and refractory skin lesions, even in recombinant human TNF-α receptor (rhTNFR)-resistant case. The take-home message from our cases is that infliximab is a useful therapeutic option for refractory PsA, especially when a patient has a combination of psoriasis and psoriatic arthritis. Further local evidence and experience must be accumulated in order to make anti-TNF-α therapy more accessible to PsA patients in China.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Antoni, C., Dechant, C., Hanns-Martin Lorenz, P.D., Wendler, J., Ogilvie, A., Lueftl, M., Kalden-Nemeth, D., Kalden, J.R., Manger, B., 2002. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum., 47(5):506-512.

[2]Antoni, C., Krueger, G.G., de Vlam, K., Birbara, C., Beutler, A., Guzzo, C., Zhou, B., Dooley, L.T., Kavanaugh, A., 2005a. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis., 64(8):1150-1157.

[3]Antoni, C., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G.R., Schneider, U., Furst, D.E., Molitor, J., Keystone, E., Gladman, D., et al., 2005b. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum., 52(4):1227-1236.

[4]Boehncke, W.H., Boehncke, S., Schön, M.P., 2010. Managing comorbid disease in patients with psoriasis. BMJ, 340:b5666.

[5]Chinese Rheumatology Association, 2004. Guideline for diagnosis and treatment in psoriatic arthritis. Chin. J. Rheumatol., 8(3):181-183 (in Chinese).

[6]Gratacos, J., Casado, E., Real, J., Torre-Alonso, J.C., 2007. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann. Rheum. Dis., 66(4):493-497.

[7]Haugeberg, G., Conaghan, P.G., Quinn, M., Emery, P., 2009. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis., 68(12):1898-1901.

[8]Moll, J.M., Wright, V., 1973. Familial occurrence of psoriatic arthritis. Ann. Rheum. Dis., 32(3):181-201.

[9]Ritchlin, C.T., Kavanaugh, A., Gladman, D.D., Mease, P.J., Helliwell, P., Boehncke, W.H., de Vlam, K., Fiorentino, D., Fitzgerald, O., Gottlieb, A.B., et al., 2009. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis., 68(9):1387-1394.

[10]Smith, N., Gadsby, K., Deighton, C., 2007. Psoriatic arthritis patients doing better on infliximab than etanercept. Rheumatology (Oxford), 46(4):721-722.

[11]Sokoll, K.B., Helliwell, P.S., 2001. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J. Rheumatol., 28(8):1842-1846.

[12]van der Heijde, D., Kavanaugh, A., Gladman, D.D., Antoni, C., Krueger, G.G., Guzzo, C., Zhou, B., Dooley, L.T., de Vlam, K., Geusens, P., et al., 2007. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum., 56(8):2698-2707.

[13]Voulgari, P.V., Venetsanopoulou, A.I., Exarchou, S.A., Alamanos, Y., Tsifetaki, N., Drosos, A.A., 2008. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Semin. Arthritis Rheum., 37(5):293-298.

[14]Wong, K., Gladman, D.D., Husted, J., Long, J.A., Farewell, V.T., 1997. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum., 40(10):1868-1872.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952276; Fax: +86-571-87952331; E-mail: jzus@zju.edu.cn
Copyright © 2000~ Journal of Zhejiang University-SCIENCE